🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

.PeerVoice presents a new program on evaluating real-world evidence for later-line treatments in advanced colorectal cancer 📖 Available for CME credit ⬇️

Bayer Oncology presents real-world data on safety and efficacy outcomes by treatment sequence in patients with #mCRPC at European Association of Nuclear Medicine (EANM). Learn more 👇 Abstract: OP-069, Session 211 #EANM24

#EANM24 A new actinium-225/francium-221 generator concept evaluates the potential contribution of recoiled daughter radionuclides to side effects in non-targeted organs 🔎 Abstract: OP-028, Session 205

Results from an in vivo model of prostate cancer describe the distribution of the alpha-emitting daughter radionuclides of actinium-225. Discover more at European Association of Nuclear Medicine (EANM). Abstract: OP-084, Session 304 ⬇️ #EANM24 #ProstateCancer

Learn more about the pharmacokinetics and biodistribution of a novel targeted alpha therapy and its daughter radionuclides at European Association of Nuclear Medicine (EANM) 👇 Abstract: OP-145, Session 504 #EANM24

An analysis of the real-world REASSURE study evaluates ALP decline after treatment with an alpha-emitting radiopharmaceutical in patients with #mCRPC. Check out the abstract to learn more 👇 Abstract: OP-688, Session 1506 #EANM24

HCPs: TMC Unilabs Academy's cutting-edge #MedEd programs are designed to enhance your skills with case simulations, improving patient outcomes in #oncology. Our latest module focuses on #Oncogene-driven paediatric cancers. Register today! shorturl.at/Wt94A

A long-term analysis of the efficacy and safety of a tropomyosin receptor kinase (TRK) inhibitor in pediatric patients with primary and non-primary CNS TRK fusion tumors is available now. Explore the latest data at #SIOPcongress 👇 Abstract: 561, Oral Presentation SIOP International

An updated analysis of efficacy, safety, and genomic data from patients with tropomyosin receptor kinase (TRK) fusion #ThyroidCancer treated with a TRK inhibitor includes longer follow-up. Learn more at #2024ATA American Thyroid Association

#CTOS2024: An updated analysis describes efficacy, safety, and treatment discontinuation outcomes of a TRK inhibitor in pediatric patients with TRK fusion sarcomas. Abstract: 69, Oral Presentation

NTRK gene fusions are oncogenic drivers in multiple tumor types, including sarcoma. Learn more about a TRK inhibitor as first-line treatment in patients with TRK fusion sarcomas at CTOS’s 2024 congress 👇 Poster Presentation #TRKFusionCancer #CTOS2024

Bayer Oncology presented long-term follow-up data from adult patients with TRK fusion sarcomas treated with a TRK inhibitor 🩺 Explore the latest efficacy and safety data at #CTOS2024! Poster Presentation

Bayer Oncology presented the latest data in precision medicine at #SNO2024 An updated analysis of the long-term efficacy and safety of a TRK inhibitor in patients with TRK fusion primary CNS tumors is available now 👇 Abstract: CTNI-07, Oral Presentation

What are the significant barriers to using AI in prostate cancer clinical practice? Axel S. Merseburger points to data protection. Listen below 👇

According to Axel S. Merseburger, AI is not the future of prostate cancer treatment – it’s the present. Want to know why? Listen below 🔈

Sometimes, medical terminology can make patients feel like physicians are speaking a foreign language. How can this be improved? Hear from Dr Castro 🎧

Everybody should have access to cancer care, no matter how remote their community may be. Hear from Dr Asiedu 🔈

It is critical to include diverse patient populations in clinical trials evaluating novel treatments for prostate cancer. Hear from Dr Asiedu 👇

A patient’s knowledge of their disease can shape both their treatment and outcomes. How? Listen to Dr George 👇

We are in a time where healthcare information is readily available. How can patients keep up with new information? Dr George shares his perspective ⬇️